Adnan Karaibrahimoglu
Overview
Explore the profile of Adnan Karaibrahimoglu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
78
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uzun M, Erden A, Ulusan S, Ozkan E, Ozseven A, Gulle K, et al.
Anatol J Cardiol
. 2025 Mar;
PMID: 40062370
Background: With the increasing incidence of cancer among the adult population, radiotherapy (RT) is frequently used as a critical component in the treatment of various cancer types. Due to the...
2.
Taskiran E, Terzi M, Helvaci E, Eser M, Avci B, Faruk T, et al.
Mult Scler Relat Disord
. 2025 Feb;
95:106307.
PMID: 39921990
No abstract available.
3.
Karaibrahimoglu A, Ince F, Hassanzadeh G, Alizadeh A, Bagheri K, Yucel I, et al.
Work
. 2024 Aug;
79(3):1577-1588.
PMID: 39093108
Background: Artificial Intelligence (AI) refers to the simulation of human intelligence in machines that are programmed to perform tasks that typically require human intelligence. The integration of AI and telehealth...
4.
Taskiran E, Terzi M, Helvaci E, Eser M, Avci B, Faruk T, et al.
Mult Scler Relat Disord
. 2024 Feb;
83:105391.
PMID: 38335838
Background/aim: Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis...
5.
Demirsoy I, Karaibrahimoglu A
Adv Clin Exp Med
. 2023 Aug;
32(8):829-838.
PMID: 37589227
The majority of Americans, accounting for 51% of the population, take 2 or more drugs daily. Unfortunately, nearly 100,000 people die annually as a result of adverse drug reactions (ADRs),...
6.
Aydin H, Aydin H, Karaibrahimoglu A, Afsar B
Adv Clin Exp Med
. 2023 Jun;
33(5):455-462.
PMID: 37341174
Background: Renal steatosis is an abnormal accumulation of fat in the kidney and may cause chronic kidney disease (CKD) or CKD progression. Objectives: This pilot study aimed to evaluate the...
7.
Ulusan S, Gulle K, Peynirci A, Sevimli M, Karaibrahimoglu A, Kuyumcu M
Anatol J Cardiol
. 2023 May;
27(6):339-347.
PMID: 37257007
Background: Doxorubicin is a widely used agent in the treatment of cancer, but the cardiotoxicity associated with this drug limits its potential for use. The cardioprotective effects of dapagliflozin, an...
8.
Aydin H, Topsakal K, Ayyildiz V, Aydin H, Karaibrahimoglu A
J Coll Physicians Surg Pak
. 2023 Jan;
33(1):20-26.
PMID: 36597230
Objective: To evaluate the late gadolinium enhancement ratio (LGER) quantitatively in late post-contrast images in multiparametric prostate MRI (mpMRI) for the differential diagnosis of chronic prostatitis and prostate cancer (PCa)....
9.
Savran M, Asci H, Erzurumlu Y, Ozmen O, Ilhan I, Sirin M, et al.
Mol Biol Rep
. 2022 Aug;
49(9):8753-8760.
PMID: 35939182
Background: Inflammatory bowel disease (IBD) is characterized with chronic inflammation of gastrointestinal track. In the pathogenesis of IBD, inflammation is the main mechanism. Induction of inflammation triggers the oxidative stress...
10.
Karaibrahimoglu A, Ayhan S, Karaagac M, Artac M
J Appl Stat
. 2022 Jun;
48(13-15):2931-2943.
PMID: 35707084
Dates have great importance in cancer diseases. However, the date variables themselves are not analyzed. This study aims to evaluate the descriptive statistics of diagnosis, operation, and last examination dates...